Abrocitinib Patent Expiration
Abrocitinib is Used for treating adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products. It was first introduced by Pfizer Inc
Abrocitinib Patents
Given below is the list of patents protecting Abrocitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cibinqo | US9035074 | Pyrrolo[2,3-D]pyrimidine derivatives | Jan 14, 2036 | Pfizer |
| Cibinqo | US9545405 | Pyrrolo[2,3-D]pyrimidine derivatives | Feb 19, 2034 | Pfizer |
| Cibinqo | US9549929 | Pyrrolo[2,3-D]pyrimidine derivatives | Feb 19, 2034 | Pfizer |
Abrocitinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Abrocitinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | Pfizer | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema | Pfizer | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age | Pfizer | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Janus Kinase Inhibition in Sarcoidosis | Yale University | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |